Bronchial asthma: new prospects in therapy

Abstract

The article reviews original and literature data on the use of monoclonal antibodies (MAB) for treatment of patients with severe bronchial asthma (BA), methods of MAB obtaining. Biomolecule targets in BA are some immunoglobulins, CD4 lymphosytes and TNFalpha. Successful use of monoclonal anti-IgE antibodies in BA by Russian clinicians in 1980s and current experience with administration of foreign MAB drugs (omalizumab, mepolizumab, infliximab, etc.) are considered.

Keywords

• bronchial asthma
• treatment
• monoclonal antibodies
• recombinant bioengineering
• omalizumab